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Abstract
Apolipoprotein E (apoE) receptors act as signaling molecules in neurons, altering phosphorylation
of numerous proteins after extracellular ligand binding and affecting neurite outgrowth, synapse
formation, and neuronal migration. Since apoE is important in the pathogenesis of Alzheimer's
disease (AD), we tested whether apoE treatment of neurons affected molecules important to
phosphorylation of tau, such as GSK 3β, P35, and CDK5, and the phosphorylation of tau itself.
Treatment of primary neurons with 2 uM apoE (or an apoE-derived peptide) decreased levels of
phospho-GSK 3β, P35 and CDK5, and decreased levels of phosphorylated forms of tau. A lower
concentration of apoE (100 nM) had no effect on these molecules. The alteration of tau
phosphorylation by apoE was blocked by an inhibitor of the low-density lipoprotein receptor family,
demonstrating the effects were due to receptor interactions. These results demonstrate that apoE
affects several downstream signaling cascades in neurons: decreased tau kinases phosphorylation
and inhibition of tau phosphorylation at Thr171 and Ser202/Thr205 epitopes. We conclude that
apoE can alter levels of tau kinases and phospho-tau epitopes, potentially affecting tau
neuropathological changes seen in AD brains.
Introduction
Alzheimer's disease (AD) is defined neuropathologically
by the presence of two types of protein aggregates: extra-
cellular senile plaques, which are composed of the Aβ
peptide, and intraneuronal neurofibrillary tangles (NFT),
which are composed of phosphorylated forms of the tau
protein [1-3]. Tau is a microtubule-associated protein
with multiple phosphorylation sites [4]; hyperphosphor-
ylation of tau in the AD brain is potentially promoted by
several kinases, including GSK 3β, CDK5, and MARK [5].
Much AD-related research focuses on identifying factors
that affect these neuropathological lesions and the risk of
AD. One genetic factor that has been identified is the
APOE genotype [6]. The APOE e4 allele is associated with
increased Aβ deposition in brain [7-9]; evidence on
whether APOE genotype also affects the accumulation of
neurofibrillary tangles is more mixed [10].
The apoE protein is associated with high-density lipopro-
teins in the CNS [11], and is increased after several types
of brain damage [12,13]. ApoE-lipoproteins bind mem-
bers of the low-density lipoprotein (LDL) receptor family
[14], receptors with complex ligand binding domains that
allow interactions with large numbers of ligands. These
receptors mediate uptake of apoE-containing lipopro-
teins, suggesting that apoE receptors could be important
in the clearance of lipids after damage [15]. But stimula-
tion of these receptors by ligands also mediates various
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neuronal signaling mechanisms. Binding of Reelin to LDL
receptor family members promotes phosphorylation of
the cytoplasmic disabled protein (Dab1) [16], and
induces activation of Src and PKB kinases [17,18]. These
processes are necessary for correct neuronal migration
during development. Furthermore, Reelin inhibits phos-
phorylation of GSK 3β, but does not affect the activity of
CDK5 [19]. We have found that apoE binding to these
receptors also promotes Dab phosphorylation and stimu-
lates intracellular activation of Src and PKB kinase [20]; it
is unknown whether apoE also affects activation of tau
kinases, and this question was the basis for the present
study. ApoE induces neurite outgrowth and microtubule
stability [21,22], and several studies have suggested that
apoE or apoE fragments can access the cytoplasmic com-
partment of cells and directly bind to tau [23] or induce
NTF-like inclusions [24]. Because apoE affects intracellu-
lar kinases through binding to its receptors, we examined
the effects of apoE signaling on the activation of tau
kinases and the phosphorylation of tau in vitro, using full-
length apoE, or an apoE peptide derived from the recep-
tor-binding region of apoE. Our results in primary neu-
rons show that apoE treatment inhibited tau kinases (e.g.,
P35, P-GSK3β, and CDK5) and tau phosphorylation.
These data suggest that apoE could alter tau phosphoryla-
tion and thus potentially affect the accumulation of NFT
in the AD brain.
Experimental procedures
Chemicals
Recombinant human apoE2, E3 and E4 were purchased
from Oxford Biomedical Research. The apoE peptide (EP;
sequence LRKLRKRLLLRKLRKRLL) was synthesized by
Johns Hopkins University of Medicine (Biosynthesis and
sequencing facility, Baltimore, MD). This peptide, con-
taining a tandem repeat of the receptor binding domain of
apoE, has the same signaling properties as full length
apoE [20]. Poly-D-lysine (P-7280) and phosphatase
inhibitor cocktails (P-2850 and P-5726) were purchased
from Sigma (St Louis, MO). CytoTox-ONE™ homogene-
ous Membrane Integrity Assay (G7891) was purchased
from Promega (Madison, WI).
Antibodies
Antibodies against phospho-GSK-3β (pY216, diluted
1:1000) and total GSK-3β were from BD Transduction
Laboratories. Mouse monoclonal antibodies against p35
(diluted 1:1000), CDK5 (1:1000) and β-actin (1:1000)
were purchased from Santa Cruz Biotechnology and BD
Pharmingen. To examine the phosphorylation of tau, the
following antibodies were used: mouse monoclonal anti-
body 5E2 (Upstate Biotechnology, diluted 1:1000), which
recognizes a phosphorylation-independent tau epitope
and is used to measure total tau; anti Tau-1 (Chemicon
International, diluted 1:1000), which recognizes an
unphosphorylated tau epitope; pS396 (Biosource Interna-
tional, diluted 1:1000), AT8 (Innogenetics, diluted
1:1000) and AT270 (Innogenetics, diluted 1:1000), which
recognize phosphorylated tau epitopes.
Neuronal cultures
Primary mouse embryonic cortical neuron cultures were
prepared from embryonic day 16 Swiss-Webster mice as
previously described [25]. Briefly, mouse E16 embryos
brain cortices were chopped and trypsinized for 10 min at
37°C. After trypsinization, 0.4 µg/ml trypsin inhibitor,
0.025% DNase and 12 mM MgSO4 were added and mixed
until the tissue was thoroughly homogenized. Cells were
then transferred to Neurobasal medium containing B27
serum supplement (Invitrogen), 1 mM glutamine, gen-
tamycin and cytosine-β-D-arabinofuranoside (Ara-C, 5
µg/ml) (Sigma). Neurons were seeded on 50 µg/ml poly-
D- lysine coated 12 well tissue culture plates at a density
of 2 × 10 6 per well. Toxicity was monitored by LDH
release using the CytoTox-ONE™ Assay. To measure the
effects of apoE on tau proteins, primary neuronal cells
were treated with buffer or apoE peptide for 2 or 12 hours.
For extraction of cells in RIPA buffer, neurons were
washed with ice-cold PBS containing 10 mM NaF, ice-cold
RIPA buffer (10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1%
Triton X-100, 1% deoxycholate, 5 mM EDTA, protease
inhibitor and phosphatase inhibitor cocktails) was added,
then cells were centrifuged at 10,000 rpm for 5 min and
the supernatant was collected. For extraction of cells in
SDS buffer, the pellet after centrifugation was incubated
with SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 2%
SDS, 25% glycerol, 0.01% Bromophenol Blue)(Bio-Rad)
including DNase for 30 min at 37°C. Additionally, cells
were extracted directly with SDS sample buffer including
DNase and incubated for 30 min at 37°C. Phosphoryla-
tion of tau and total tau levels were then measured in the
SDS buffer extract, RIPA buffer extract, or in the SDS
buffer extract following RIPA buffer extraction.
Immunoblotting
Proteins from cell extracts were separated under dena-
tured and reduced conditions by Tris-glycine polyacryla-
mide gel electrophoresis. Separated proteins were
transferred onto PVDF membrane at 170 mA for 2 hours
and blocked with 5% nonfat dry milk or 4% BSA. The
blots were incubated with antibodies at room temperature
for 1 hour. Horseradish peroxidase-conjugated secondary
antibody was visualized by ECL detection system and
exposed to film. Films were scanned using a ScanMaker
9800XL densitometer (Microtek), and relative levels of
bands on a film were compared using Jandel SigmaStat
software.Molecular Neurodegeneration 2006, 1:18 http://www.molecularneurodegeneration.com/content/1/1/18
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Statistical analysis
Experiments were repeated a minimum of four times
unless otherwise noted. All data was analyzed using
ANOVA with Graphpad Prism 4 software, using Tukey's
Multiple Comparison test for post-hoc analyses with sig-
nificance determined as P < 0.05. Descriptive statistics
were calculated with StatView 4.1 and displayed as an
expressed mean ± S.E.M.
Results
ApoE inhibits tau kinases in primary neurons
Since apoE altered activation of kinases including JNK,
AKT and ERK1/2 in primary neurons [20], we tested
whether apoE treatments also altered activation of several
kinases potentially involved with phosphorylation of tau.
We treated neurons with 2 uM apoE peptide for 2 hours,
a treatment that increased AKT and ERK activation and
decreased JNK activation [20]. This treatment decreased
levels of P35, CDK5 and the phosphorylated form of GSK
3β (Fig. 1, left panel); no significant changes in levels of
total GSK 3β or β-actin were observed. We did not observe
production of P25, the active cleaved fragment of P35,
under any conditions. Quantification of these blots
revealed significant three to four fold decreases in total
P35, total CDK5 and phospho-GSK 3β (Fig 1B, left panel).
We also examined whether apoE concentrations normally
found in CSF (approximately 100 nM [26]) altered levels
of these kinases after 12 hours. This dose did not affect
AKT, ERK, and JNK activation in vitro [20]. Similarly,
apoE peptide at 100 nM for 12 hours did not change levels
of phospho-GSK 3β, P35 and CDK5 (Fig. 1A, B, right pan-
els). Thus, this apoE peptide induces reductions in various
tau kinases, but only at concentrations above endogenous
apoE levels.
We tested whether purified apoE isoforms also inhibited
tau kinases. Exposure of cultured neurons to 2µM apoE2
or E4 decreased levels of phosphorylated GSK 3β and P35
(Fig. 2A). No significant changes in β-actin were observed
after treatment with apoE isoforms (Fig. 2A). We quanti-
fied the changes in phospho-GSK 3β and P35; decreases in
activation of GSK 3β (by 80% and 36 % for apoE2 and E4,
respectively) were observed for the two apoE isoforms
(Fig. 2B). ApoE2 and apoE4 also caused significant
decreases in P35 (by 96% and 79%, respectively; Fig. 2B).
We also examined whether apoE2 or apoE4 could affect
these kinases at concentrations consistent with those
observed in CSF (100 nM). We treated neurons with 100
nM apoE peptide for 12 hours, and found that these treat-
ments did not change levels of phospho-GSK 3β (Fig. 2C,
D). However, treatment of cells with 100 nM apoE2
slightly decreased levels of P35, by 23% (Fig. 2C, D),
although apoE4 had no significant effects. No significant
changes in β-actin were observed.
ApoE decreases tau phosphorylation in primary neurons
We tested whether apoE treatments that decreased phos-
pho-GSK 3β, P35, and CDK5 also decreased tau phospho-
rylations. We treated neurons for two hours with 2 uM
apoE peptide, and extracted cell proteins in RIPA buffer.
Levels of unphosphorylated tau, as measured by the Tau-
1 antibody, were significantly increased by the apoE pep-
tide (Fig. 3A). We blotted lysates with the anti-phospho-
tau antibody AT8, which recognizes the phosphorylated
residues of Ser202/Thr205 on the tau protein. ApoE pep-
ApoE peptide (EP) affects tau kinases in primary neurons Figure 1
ApoE peptide (EP) affects tau kinases in primary neurons. 
Cultured primary neurons were treated with buffer or EP, a 
tandem repeat of the receptor-binding domain of apoE. Panel 
A: Cells were treated with control buffer ("C") or EP at 2 uM 
for 2 hours (left panels) or 100 nM overnight (right panels). 
Cell lysates (20 ug/lane) were electrophoresed and immuno-
blotted for phospho-GSK 3β (P-GSK 3β), total GSK 3β, P35, 
CDK5 and β-actin. β-Actin was measured from the same 
blots to ensure that equal protein was present in every lane. 
Panel B: Quantification of these blots revealed a significant 
decrease (*P < .05) in levels of P-GSK 3β(4 fold decrease), 
P35 (3.5 fold decrease), and CDK5 (5 fold decrease) with 
2uM EP treatment. However, no significant decreases were 
noted with 100nM EP treatment. Histographs show mean +/- 
standard error, n = 4.Molecular Neurodegeneration 2006, 1:18 http://www.molecularneurodegeneration.com/content/1/1/18
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tide treatment significantly reduced levels of this phos-
phorylated form of tau (Fig. 3A). Similarly, anti-phospho-
tau antibodies AT270 and PS396, which recognize the
phosphorylated residues of Thr171 and Ser396 on the tau
protein respectively, also showed significantly reduced
levels in apoE peptide treated cells as compared to cells
treated with buffer alone (data not shown, and Figure 5).
Quantification of these blots revealed that the apoE pep-
tide induced a 115% increase in levels of unphosphor-
ylated tau and a 70–90% decrease in phospho-tau
proteins (Fig 3E).
Surprisingly, we found that the levels of total tau were also
significantly altered by the treatments with apoE peptide
in this short (2 hour) period. Immunoblots with the anti-
body 5E2 (which recognizes tau irrespective of its phos-
phorylation state) demonstrated that levels of tau in cell
extracts decreased by 69% (Figure 3A). We were con-
cerned that all tau species were efficiently extracted in the
RIPA buffer used, given that tau is microtubule-associated
and thus might remain associated with cell debris after
extraction. Therefore, we repeated the experiments,
extracting the cells in RIPA buffer, and then extracting the
insoluble fractions in SDS buffer (after treatment with
DNase to decrease the viscosity of the extracts). Under
these conditions, we did not observe significant decrease
of total tau after EP treatment (Fig 3F), suggesting that
apoE affected the proportion of total tau solubilized by
RIPA, and apoE did not decrease the total levels of tau. As
a further test of this hypothesis, we also extracted cells
directly into the stronger buffer containing SDS. We found
that the total level of tau observed was not decreased, but
apparently increased after apoE peptide treatment (Figure
3G). We also found that the level of unphosphorylated
tau (Tau-1) was still increased and the level of phospho-
tau (AT8) was still decreased (Figure 3G) in the SDS
extraction buffer. Thus, the apoE peptide treatment caused
both a change in the phosphorylation state of tau, as well
ApoE peptide and apoE isoforms affect phosphorylation of  tau in primary neurons Figure 3
ApoE peptide and apoE isoforms affect phosphorylation of 
tau in primary neurons. Primary neurons were treated with 
control buffer ("C") or 2 uM EP (panel A), E2 (B), E3 (C) and 
E4 (D) for two hours. Cells were lysed in RIPA buffer (n = 4) 
and cell proteins (20 ug/lane) were separated by SDS-PAGE. 
Relative levels of tau epitopes were determined by immuno-
blotting with the indicated antibodies: anti-5E2, a measure of 
total tau; Tau 1, a measure of nonphosphorylated tau; pS396, 
AT8 and AT270, measures of phospho-tau epitopes. EP, E2, 
E3 resulted in increased Tau-1 immunoreactivity and 
decreased phosphorylation of tau at several sites. Quantifica-
tion of these blots revealed that the apoE peptide induced a 
115% increase in levels of unphosphorylated tau and a 70–
90% decrease in phospho-tau proteins (panel E). Similar 
experiments with EP were conducted, but cells were 
extracted either RIPA buffer and sequentially in the stronger 
SDS buffer (panel F) or directly in the SDS buffer (panel G). A 
similar increase in non-phosphorylated tau and a decrease in 
phosphorylated tau were observed, but the levels of total tau 
were increased by EP treatment, in contrast to the decrease 
seen in panels A-D.
ApoE isoforms reduce phosphorylation of GSK 3β and P35 Figure 2
ApoE isoforms reduce phosphorylation of GSK 3β and P35. 
Panel A: Cells were treated with control buffer ("C"), apoE2 
("E2"), or apoE4 ("E4") at 2 uM for 2 hours. Cell lysates (20 
ug/lane) were electrophoresed and immunoblotted for P-
GSK 3β, P35, and β-actin. ApoE2 and E4 treatment resulted 
in decreased levels of P-GSK3β and P35. Panel B: ApoE2 
caused the greatest decreases in GSK 3β phosphorylation, 
and apoE4 the least, with significant differences observed 
between each of the apoE isoforms. Both E2 and E4 caused 
significant decreases in P35, 96% and 79%, respectively. Panel 
C: Cells were treated with control buffer, E2, or E4 at 100 
nM for 12 hours. Cell proteins were probed for P-GSK 3β, 
P35 and β-actin. Panel D: Neither apoE isoform at 100 nM 
had a significant effect on P-GSK3β and P35 levels.Molecular Neurodegeneration 2006, 1:18 http://www.molecularneurodegeneration.com/content/1/1/18
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as a change in the distribution of the tau protein to alter
its extraction in different buffers.
We tested whether similar changes occurred after treat-
ment of cells with each of the full-length apoE isoforms.
Each of the three apoE isoforms caused a decrease in the
levels of phosphorylated tau (Fig. 3B, C, D). No signifi-
cant changes in β-actin were observed. Interestingly,
quantification of these blots revealed that apoE4 had the
smallest effect of the three isoforms on tau phosphoryla-
tion state: it slightly increased levels of unphosphorylated
tau (21%) and decreased phospho-tau proteins (35%).
We also examined whether the lower dose of apoE (100
nM) inhibited tau phosphorylation. We found that treat-
ment of cells with 100 nM apoE2 (Fig 4A, left panel) or
100 nM apoE4 (Fig 4A, right panel) did not change levels
of tau phosphorylation compared with control (Fig 4A)
after 12 hour treatments. No significant changes in β-actin
were observed. Quantification of these blots revealed no
significant changes in AT270, AT8 and PS396 (Fig 4B). We
tested whether the lower dose of EP had an effect after the
shorter period of time used in Figures 1–3 for the higher
dose of EP. We observed no changes in levels of kinases,
phospho-GSK-3β or CDK5 (Figure 4C). We also observed
no differences in the levels of phospho-tau, as measured
by the AT8 or AT270 antibodies (Figure 4C). Thus, the
effects of apoE on tau kinases and tau phosphorylation
only occurred after treatments with high levels of apoE or
apoE peptide.
Reduction in tau phosphorylation depends on apoE-
receptor interaction
In order to test whether the observed changes to tau phos-
phorylation in primary neurons were mediated by mem-
bers of LDL receptor family or were some direct effect of
apoE, we pre-treated cells with RAP, an inhibitor of these
receptors. RAP causes a prolonged redistribution of apoE
receptors from dendritic to somatic compartments, poten-
tially preventing signaling by treatments with subsequent
ligands [25]. RAP treatment alone did not affect levels of
phospho-tau epitopes (Fig. 5A, B). Treatment of neurons
with the apoE peptide caused the significant decrease in
phospho-taus (Thr 171, Ser202/Thr205), but these
decreases were inhibited by pretreatment of cells with RAP
(Fig. 5A, B, first row). The Src kinase inhibitor PP2 and the
ERK kinase inhibitor PD98059 did not block the decrease
in tau phosphorylation by apoE peptide (Fig. 5A, second
and third row). No significant changes in β-actin were
observed. These data suggest that decreases in phosphor-
ylation of tau required binding of the apoE peptide to LDL
receptor family members, but did not involve ERK or Src
kinase cascades.
Discussion
We have investigated how apoE signaling affects tau
kinase activity and tau phosphorylation in primary neu-
rons. In primary neurons, treatment of cells with 2 uM
apoE (but not 100 nM) inhibited phosphorylation of GSK
3β, and decreased levels of P35 and CDK5 (Fig. 1). ApoE
also decreased the levels of phosphorylated tau and
increased the levels of unphosphorylated tau (Fig. 3).
These treatments may also have altered the distribution of
tau in the neurons, since increased levels of tau (but
decreased levels of phosphorylated tau) were recovered in
easily solubilized cell fractions (Fig. 3). These effects were
mediated by members of the LDL receptor family, since
their effects were blocked by the inhibitor RAP (Fig. 5).
Although apoE receptors were initially thought to func-
tion to endocytose ligands, several other functions of lig-
and binding have now been described. ApoE receptors
transduce signals important for neuronal migration dur-
ing development [27]. Ligand interactions with apoE
receptors result in transient changes in Src, ERK and JNK
phosphorylation [20,28]. ApoER2 interactions with
NMDA receptors are modulated by ligand binding [29].
In glia, apoE receptors mediate anti-inflammatory effects
of apoE [30]. Finally, in several cell types, ligand binding
Panel A: Primary neurons were treated with control buffer  ("C") or 100 nM apoE2 (left panel) and E4 (right panel) for 12  hours Figure 4
Panel A: Primary neurons were treated with control buffer 
("C") or 100 nM apoE2 (left panel) and E4 (right panel) for 12 
hours. Cells were lysed in RIPA buffer (n = 4) and cell pro-
teins (20 ug/lane) were separated by SDS-PAGE. Relative lev-
els of tau epitopes were determined by immunoblotting with 
5E2, Tau-1, and AT8 antibodies. Neither apoE2 (100nM) nor 
E4 (100nM) significantly changed the levels of tau phosphor-
ylation compared with control. No significant changes in β-
actin were observed. Panel B: Quantification of these blots 
revealed no significant changes in 5E2, Tau-1, and AT8. N = 4 
for all blots listed above and their quantification averages are 
what is depicted in the figure. Panel C: Primary neurons were 
treated with control buffer ("C") or 100 nM EP for two 
hours, and cellular proteins analyzed by immunoblot for 
phospho-GSK-3β, CDK5, AT8, AT270 and β-actin as above.Molecular Neurodegeneration 2006, 1:18 http://www.molecularneurodegeneration.com/content/1/1/18
Page 6 of 8
(page number not for citation purposes)
to apoE receptors increases the surface cleavage of the
receptors [31]. Ligands for this family of receptors differ
somewhat in whether they are freely able to be endocy-
tosed (such as apoE), or whether they are attached to
other cells or to the extracellular matrix (such as reelin). It
will be interesting to determine whether there are differ-
ences in the signaling effects of ligands depending on
whether their metabolism depends on endocytosis by
apoE receptors.
These results complement studies of mouse knock-out
models. Brains of APOE knock-out mice have increased
levels of tau phosphorylation compared to wild-type con-
trols [32,33]. Similarly, brains of Reeler mice, ApoER2-/-/
VLDLr-/- mice, and Dab-1 knock-out mice have hyper-
phosphorylated tau [34]. Thus, chronic interruption of
the apoE signaling pathway leads to increased tau phos-
phorylation in brain. Acute treatment of neurons with ree-
lin caused decreased GSK-3β activation [16], and we
report that treatment with apoE also caused decreased
GSK-3β activation as well as reduced tau phosphoryla-
tion. Thus the acute effects of apoE and reelin are similar
to each other, and consistent with the effects of chronic
absence of apoE and reelin in vivo.
The fact that apoE affects the phosphorylation of the
microtubule-associated protein tau is supportive of a
function of apoE in promoting neurite outgrowth
[25,35,36]. ApoE levels are induced after several types of
brain damage [12,13], presumably as a mechanism for
clearance of damaged membranes [37]. However, this
apoE could also act as a signal for neurons to stabilize new
neurites as a mechanism for regeneration after damage
[38]. ApoE could alter the stability of the microtubules by
altering tau and phospho-tau levels, allowing permanent
changes to the neuronal cytoskeleton that need to accom-
pany neurite outgrowth.
In the AD brain, the APOE genotype affects levels of Aβ
deposition [7,8], and apoE is a component of most
plaques [39,40]. In fact, because of its strong affinity for
Aβ, apoE has been referred to as a pathological chaperone
[41]. The presence of the apoE receptor binding domain
on amyloid deposits [40] suggests that apoE on plaques
could provide chronic signals via apoE receptors to neu-
rons in the vicinity of plaques. These signals could include
increased phosphorylation of substrates of kinases such as
ERK and Src [20] or decreased phosphorylation of sub-
strates of kinases such as JNK [20], GSK 3β and CDK5 (Fig
1). Since kinases in both groups have been linked to
increased tau phosphorylation (e.g. ERK [42] and GSK-3β
[43]), apoE presence on plaques could contribute both to
the formation and the inhibition of phospho-tau-positive
dystrophic neurites found around neuritic plaques. We
previously have found different strengths of the signaling
effects for the apoE isoforms. ApoE2 had the most effect
on ERK activation and JNK inhibition [20] and apoE4 the
least; a similar pattern was observed for the different apoE
isoforms on receptor cleavage [31]. In this study, apoE2
decreased levels of phospho-GSK-3β and CDK5 more
than apoE4 (Figure 2). If the acute effects of apoE on neu-
rons applied to more chronic exposures, apoE2 on
plaques would be expected to inhibit phospho-tau levels
the most, and apoE4 would be expected to have the least
effect. Several studies have indicated that higher levels of
phospho-tau in AD brain are associated with apoE4 than
with apoE3 or apoE2 [42], correlating with the in vitro
effects of these isoforms on GSK-3β and CDK5 inhibition
(and not with their effects on ERK activation).
Animal models have also implicated apoE in disruption
of neuronal cytoskeleton. Neuronal expression of apoE4
is associated with prominent axonopathy [44] and
increased tau phosphorylation [42,45]. These processes
may involve intraneuronal proteolysis of apoE [45].
Expression of APOE is glial under most conditions, but
ApoE receptor inhibition alters tau phosphorylation Figure 5
ApoE receptor inhibition alters tau phosphorylation. Primary 
neurons were pre-incubated in the presence of inhibitors 
("i") (lanes 3 and 4) for 2h and then either exposed to con-
trol buffer ("C") (lanes 1 and 3) or 2 µM apoE peptide ("EP") 
(lane 2 and 4). Inhibitors used were RAP (1 µM), PP2 (1 µM), 
or PD98059 (10 µM). Cell extracts were was examined by 
immunoblots with AT8 (n = 4, left panel), AT270 (n = 4, mid-
dle panel) or 5E2(n = 4, right panel). RAP significantly 
reversed the effect of the apoE peptide on tau phosphoryla-
tion and total tau. PP2 and PD98059 treatments showed no 
significant changes. Panel B: Quantification of RAP blots (n = 
4) demonstrated significant reversal of the effects that apoE 
(2uM) has on various tau and phospho-tau epitopes (p < 
0.02).Molecular Neurodegeneration 2006, 1:18 http://www.molecularneurodegeneration.com/content/1/1/18
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studies of the APOE promoter demonstrate that under
some kainic acid treatment condition [46], APOE may be
expressed in neurons. Under some conditions, apoE may
be present within the neuronal cytoplasm [21], where
more direct effects on tau and microtubules are possible.
ApoE directly inhibits GSK-3β phosphorylation of tau
[47] and apoE alters the pattern of tau phosphorylation by
GSK-3β [43]. These effects of apoE would not depend on
interactions with apoE receptors, as we observed here
(Figure 5).
In this study, we report that apoE can decrease levels of tau
kinases and phospho-tau proteins via extracellular inter-
actions with apoE receptors. These effects of apoE could
be important for the strong association of the APOE gene
with risk of AD.
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